Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].

Ciudad A, Alvarez E, Bousoño M, Olivares JM, Gómez JC.

Actas Esp Psiquiatr. 2007 Mar-Apr;35(2):105-14. Spanish.

PMID:
17401781
2.

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

Alvarez E, Ciudad A, Olivares JM, Bousoño M, Gómez JC.

J Clin Psychopharmacol. 2006 Jun;26(3):238-49.

PMID:
16702888
4.

Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.

Ciudad A, Olivares JM, Bousoño M, Gómez JC, Alvarez E.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1515-22. Epub 2006 Jul 3.

PMID:
16820255
5.

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group.

J Clin Psychiatry. 2004 Mar;65(3):312-21.

PMID:
15096069
6.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry. 2013 May 22;13:143. doi: 10.1186/1471-244X-13-143.

7.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
8.

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.

Bobes J, Garc A-Portilla MP, Rejas J, Hern Ndez G, Garcia-Garcia M, Rico-Villademoros F, Porras A.

J Sex Marital Ther. 2003 Mar-Apr;29(2):125-47.

PMID:
12623765
9.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400
11.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
12.

A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.

Sacchetti E, Valsecchi P, Parrinello G; QUERISOLA Group.

Schizophr Res. 2008 Jan;98(1-3):55-65. Epub 2007 Oct 15.

PMID:
17933497
13.

Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.

Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G.

Value Health. 2004 Sep-Oct;7(5):569-84.

14.

An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.

Mozes T, Ebert T, Michal SE, Spivak B, Weizman A.

J Child Adolesc Psychopharmacol. 2006 Aug;16(4):393-403.

PMID:
16958565
15.

Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.

Ciudad A, Montes JM, Olivares JM, Gómez JC; EFESO Study Group.

Eur Psychiatry. 2004 Sep;19(6):358-65.

PMID:
15363475
16.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
17.
18.

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL.

J Clin Psychiatry. 2000 Nov;61(11):833-40.

PMID:
11105736
19.

A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.

Knegtering H, Boks M, Blijd C, Castelein S, van den Bosch RJ, Wiersma D.

J Sex Marital Ther. 2006 Jul-Sep;32(4):315-26.

PMID:
16709552
20.

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD.

J Clin Psychopharmacol. 1997 Oct;17(5):407-18.

PMID:
9315992

Supplemental Content

Support Center